Bengaluru company unveils cancer atlas mapping genomic diversity to bridge data gap

While over 70% of cancer patients live in Asia, West Asia and Latin America, less than 10% of current cancer genomic data represents them. GCDA aims to bridge this disparity to ensure all populations are accurately represented in precision oncology.

A private firm in Bengaluru unveiled a Global Cancer Diversity Atlas (GCDA) on May 14 with the aim of addressing the genomics data gap in cancer care.

The atlas was launched by Infosys co-founder N. R. Narayan Murthy. The initiative is aimed at addressing a critical gap in global cancer research — the lack of genomic data from diverse populations.

While most cancer genomic datasets are dominated by Western populations, the GCDA designed by 4baseCare, a precision oncology company, is built on real-world data from India and the global South.

While over 70% of cancer patients live in Asia, West Asia and Latin America, less than 10% of current cancer genomic data represents them. GCDA aims to bridge this disparity to ensure all populations are accurately represented in precision oncology.

The company claims that GCDA is the most inclusive cancer genomics dataset, transforming how it develops diagnostics, conducts research, and delivers cancer care.

By integrating region-specific genomic insights, GCDA empowers clinicians with tools for more accurate diagnosis and targeted treatments, helping to eliminate misdiagnoses and enhance outcomes for patients worldwide.

Mr. Murthy also launched the company’s genomics lab in Mahadevapura. The lab will offer advanced genomic testing solutions, including comprehensive gene panels, whole exome sequencing and transcriptome analysis.